- Ehlers-Danlos Syndrome patient Ellen Smith serves as advocate for pain relief access
- Chronic pain sufferer Dennis Kinch pens book to encourage pain community
- Smooth Gator launches 60 Second Pain Relief
- Nuvo Research's Pennsaid 2% approved to treat pain associated with osteoarthritis of the knee
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.
The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.
“The commercial availability of Krystexxa marks another significant milestone for both patients and the company, as it is the first FDA-approved therapy that addresses a significant unmet medical need in the treatment of chronic gout in adult patients refractory to conventional therapy,” Savient president Paul Hamelin said in a statement.